Abiomed seeks US approval for artificial heart:
This article was originally published in Clinica
Abiomed has submitted to the US FDA an application to market its a fully implantable heart replacement, AbioCor. The Danvers, Massachusetts firm is seeking approval under humanitarian device exemption (HDE) regulations, which allow for the product to be made commercially available as a treatment for a defined subset of not more than 4,000 irreversible end-stage heart failure patients. The AbioCor system is currently the subject of an initial clinical trial that has been approved by FDA. 14 of the initial 15 patients have been enrolled in the trial thus far. However, Abiomed notes that it is not required to enrol a 15th patient before submitting for approval under the HDE.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.